Know Cancer

or
forgot password

A Prospective Non-Interventional Study Of China Early Invasive Breast Cancer Patients Receiving Adjuvant Therapy With Aromasin®


N/A
18 Years
N/A
Open (Enrolling)
Female
Breast Neoplasms

Thank you

Trial Information

A Prospective Non-Interventional Study Of China Early Invasive Breast Cancer Patients Receiving Adjuvant Therapy With Aromasin®


This is non-interventional study and single arm study. N/A


Inclusion Criteria:



- Early invasive breast cancer (T1-4N1-3M0) confirmed by histology or cytology.

- ER positive.

- The patient must be postmenopausal woman.

- The patient has received adjuvant Tamoxifen therapy for up to 2-3 years and will
switch to receive Aromasin® treatment (The decision to prescribe Aromasin® will
necessarily precede and will be independent of the decision to enroll patients in the
study).

Exclusion Criteria:

- Following the adjuvant Tamoxifen therapy for 2-3 years and prior to receiving
Aromasin® treatment, there is evidence of a local relapse or distant metastasis of
breast cancer, or a second primary cancer.

- Following the adjuvant Tamoxifen therapy for 2-3 years and received other aromatase
inhibitors (not Aromasin®).

Type of Study:

Observational

Study Design:

Time Perspective: Prospective

Outcome Measure:

Time-to-event, where event is defined as the earliest occurrence any of the following: Locoregional/distant recurrence of the primary breast cancer; Appearance of 2nd primary or contralateral breast cancer; Death

Outcome Time Frame:

7 years

Safety Issue:

No

Principal Investigator

Pfizer CT.gov Call Center

Investigator Role:

Study Director

Investigator Affiliation:

Pfizer

Authority:

United States: Food and Drug Administration

Study ID:

A5991093

NCT ID:

NCT01176916

Start Date:

February 2011

Completion Date:

December 2017

Related Keywords:

  • Breast Neoplasms
  • breast cancer
  • Aromasin
  • adjuvant chemotherapy
  • endocrine therapy
  • Breast Neoplasms
  • Neoplasms

Name

Location